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Abstract
Background: Mean platelet volume (MPV), which is commonly used as a measure of platelet size, indicates the rate
of platelet production and platelet activation. We aimed to evaluate the mean platelet volume in children with
hepatitis A.
Methods: In this retrospective case-controlled study, the study population consisted of 62 children with hepatitis A
and 62 healthy control subjects.
Results: MPV values, aspartate transaminase (AST), and alanine transaminase (ALT) levels on admission were
significantly increased in patients with hepatitis A when compared to controls whereas white blood cell (WBC)
counts were significantly lower. Two weeks after admission, the MPV values showed a significant decrease from 9.
47 ± 1.62 to 8.84 ± 1.48 fL in patients with hepatitis A, but these values were still significantly higher than the
controls. There was a significant difference in terms of MPV, WBC, AST, and ALT values between the controls and
the patient group 2 weeks after admission.
Conclusions: This study is the first to evaluate the MPV levels in children with hepatitis A. MPV values were found
to be increased in children hospitalized with hepatitis A.
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Background
Hepatitis A is inflammation of liver that results from in-
fection with the hepatitis A virus (HAV). It can range in
severity from a mild illness lasting a few weeks to a severe
illness lasting several months. During hepatic viral infec-
tion, various cytokines play roles in viral clearance and tis-
sue damage. Changes in cytokine activities might favor
viral persistence and consequently disease progression [1].
Mean platelet volume (MPV), which is commonly used
as a measure of platelet size, indicates the rate of platelet
production and platelet activation [2]. It also reflects the
existence of thrombotic and inflammatory processes. Pre-
viously, MPV values have been studied in hepatic diseases
such as non-alcoholic fatty liver disease (NAFLD), hepa-
titis B and hepatitis C [3–8]. Increased levels of MPV in
chronic hepatitis B and C were associated with the degree
of the liver inflammation and liver fibrosis [6–8]. Higher
MPV in NAFLD patients was reported to indicate possible
cardiovascular disease risk increase [3].
Different serum cytokine profiles in distinct clinical
profiles of hepatitis A have been described [1]. MPV
levels may reflect the cytokine levels and the inflamma-
tory process in hepatitis A. To the best of our know-
ledge, MPV values have not been previously assessed in
patients with hepatitis A. We aimed to investigate the
MPV values in patients with hepatitis A at an early stage




Data of all children who were hospitalized with diagnosis
of hepatitis A in Konya Training and Research Hospital
Pediatrics Clinic between January 2012 and January 2013
were retrospectively reviewed. These patients had re-
quired hospitalization because of severe nausea and
vomiting. The patients were considered eligible for par-
ticipation if the clinical case definition of hepatitis A of
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the Centers for Disease Control and Prevention, which
is “an acute illness with discrete onset of symptoms and
either jaundice or elevated serum aminotransferase
levels and a positive immunoglobulin M antibody to
HAV (anti-HAV) serologic result”, was met [9]. Patients
with any other infectious disease or chronic disease in-
cluding hematologic and hepatic diseases were not en-
rolled into the study.
The following data were collected by using the com-
puterized patient database: complete blood count includ-
ing white blood cell (WBC), platelet counts, activated
partial thromboplastin time (aPTT), prothrombin time
(PT), MPV, aspartate transaminase (AST), alanine trans-
aminase (ALT), and bilirubin, at the time of diagnosis
and 2 weeks after admission.
A total of 62 children with hepatitis A and 62 age- and
gender-matched healthy controls were enrolled in the
study. The healthy subjects were children who applied
to hospital for routine check-up. Control group subjects
were recruited from hospital records of these children.
Children with any sign of infection or systemic illness
were excluded from the control group. The laboratory
parameters of the healthy children were recorded from
the same computerized database. The complete blood
count analyses were performed in the same Coulter
analyzer (Sysmex XE-2100, Sysmex Corporation, Kobe,
Japan) in the central laboratory of our institution. Stand-
ard tubes with constant amount of ethylenediaminetetra-
acetic acid were used. Standard liver function tests (ALT,
AST) and bilirubin levels were measured with an auto
analyzer. Anti-HAV was analyzed by a chemiluminescent
microparticle immunoassay method.
Statistical analysis
Data were reported as mean ± standard deviation. If not
normally distributed, parameters were presented as me-
dian (minimum-maximum). The Kolmogorov-Smirnov
test was applied to check the distribution of parameters.
Differences in the means of variables were evaluated
using both parametric and nonparametric tests depend-
ing on the distribution of the variables. Paired samples t
test or Mann-Whitney U test was used to compare
groups. Paired samples t test or Wilcoxon signed-rank
test was used to compare values of the patients with
hepatitis A, on admission and 2 weeks after admission.
Results were considered significant if p < 0.05. Statistical
analysis was performed using a computer software pack-
age (SPSS for Windows, version 15.0).
Results
Table 1 shows clinical characteristics of the patients on
admission and 2 weeks after the admission and charac-
teristics of the controls. MPV values and AST and ALT
levels on admission were significantly increased in
patients with hepatitis A when compared to the controls
(p < 0.0001, p < 0.0001, and p < 0.0001, respectively)
whereas WBC counts were significantly lower (p =
0.023). Two weeks after admission, we found a signifi-
cant decrease in the MPV values, from 9.47 ± 1.62 to
8.84 ± 1.48 fL, in patients with hepatitis A, but these
values were still significantly higher than the controls.
There was a significant difference in terms of MPV,
WBC, AST, and ALT values between the controls and
the patient group 2 weeks after admission (p < 0.0001, p
= 0.021, p = 0.004, and p < 0.0001, respectively).
Discussion
To the best of our knowledge, this is the first study to
evaluate the MPV values in children with hepatitis A.
We demonstrated that MPV values were higher in chil-
dren with hepatitis A compared to healthy control
subjects.
MPV is one of the platelet function marker that re-
flects platelet production rate and stimulation. It also re-
flects the existence of thrombotic and inflammatory
processes. MPV elevates when both platelet production
and destruction are increased, which is mediated by cy-
tokines such as interleukin (IL)-3, IL-6, and thrombo-
poietin. IL-3 or IL-6 regulate megakaryocyte ploidy and
can contribute the production of more reactive and lar-
ger platelets [2]. Gasparyan et al. reported that an in-
creased MPV is a reflection of both proinflammatory
and prothrombotic conditions, where thrombopoietin
and numerous inflammatory cytokines (e.g., IL-1, IL-6,
tumor necrosis factor alpha (TNF-α)) regulate thrombo-
poiesis. They also mentioned in their review that an in-
crease in the entry of young platelets into circulation
from the bone marrow causes an increase in MPV
values, due to increased inflammatory cytokines in pa-
tients with inflammatory diseases such as familial Medi-
terranean fever and Behçet disease. They suggested that
MPV could be a useful biomarker for inflammation and
thrombosis and increases of MPV values are associated
with low-grade inflammation [10]. In our study 2 weeks
after admission, we found a significant decrease in the
MPV values, from 9.47 ± 1.62 to 8.84 ± 1.48 fL, in pa-
tients with hepatitis A, but these values were still signifi-
cantly higher than the controls. As the clinical course of
hepatitis A takes several weeks, this finding in our study
may reflect the inflammatory process in hepatitis A.
Different serum cytokine profiles in distinct clinical
profiles of hepatitis A have been described [1]. In con-
trast with most infectious diseases, acute viral hepatitis
is characterized by a lack or only a moderate degree of
acute phase reaction, which takes an asymptomatic
course, especially in children [11]. Torre et al. reported
that serum levels of IL-1a, IL-6, and TNF-α were in-
creased during the acute phase of the disease. This
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elevation was explained by the fact that the liver is an
important site of production as well as a major site of
clearance of these cytokines [12]. Müller et al. demon-
strated that production of TNF by peripheral blood
monocytes was reduced in patients with acute hepatitis
B infection but not in those with acute hepatitis A [13].
On the other hand, Muto et al. reported normal levels of
TNF-α in patients with acute hepatitis A or B without
fulminant liver failure [14]. Müller et al. studied IL-6
and IL-1 levels in patients with hepatitis A in two differ-
ent studies. He demonstrated normal levels of IL-6 and
severely decreased during the first week and gradually
increased IL-1 levels during the further course of hepa-
titis A [11, 15]. Fierro et al. reported an over expression
of TNF-α, IL-1, and IL-6 in children with HAV-induced
intermediate liver damage while minor liver damage was
characterized by increase of IL-8 and transforming
growth factor beta, suggesting that an imbalance in the
inflammatory cytokines occurs during the course of
hepatitis A [1]. In the study of Szkaradkiewicz et al., the
course of acute self limited hepatitis B was associated
with preferential T helper1-type response, which was
manifested by elevated production of interferon gamma
and IL-2 [16]. We think that increased levels of proin-
flammatory cytokines had caused elevation of MPV in
patients with hepatitis A in the current study.
Almost all studies regarding MPV values in hepatic
diseases demonstrate increased MPV values. An increase
in MPV has been reported in patients infected with
hepatitis B virus and hepatitis C virus and was related to
the increase in the entry of newly produced platelets into
circulation, which are larger in volume. The breakdown
of platelets in the spleen and increased levels of IL-6
production secondary to inflammation in the fibrosis
process were thought to contribute increased MPV in
patients with chronic hepatitis B (CHB) [6–8]. Ceylan et
al. also observed an increase in MPV in patients with
chronic hepatitis B predicting the degree of liver inflam-
mation [6]. An increase in MPV is also reported in
chronic hepatitis B patients with inactive disease [5].
Ekiz et al. reported a correlation of MPV and liver fibro-
sis and hypothesized that increased levels of IL-6 pro-
duction secondary to inflammation in the fibrosis
process may cause increased MPV in CHB [8]. A study
conducted on patients with chronic hepatitis C (CHC)
and CHC with advanced fibrosis reported an increase of
MPV at the time of diagnosis and in the post-treatment
period. This was attributed to be an early sign of ad-
vanced liver fibrosis that is warning sign for forthcoming
decompensation in these patients [7]. The results of
Ozhan et al.’s study showed also that MPV was in-
creased in patients with NAFLD, which is serving as a
surrogate marker of cardiovascular risk in this clinical
setting [3]. Cho et al. report that thrombopoietin, which
is synthesized in the liver could play a role to increase
MPV in hepatic diseases. Moreover, several cytokines,
inflammatory mediators, and growth factors may affect
MPV [4]. In addition to elevation of cytokine levels,
thrombopoietin might also have contributed the increase
of MPV in our patients with hepatitis A.
We demonstrated increased MPV values in patients
hospitalized with hepatitis A for the first time in litera-
ture. In view of the results of the studies discussed
above, we speculate that increased proinflammatory
Table 1 Demographic and laboratory characteristics of patients with hepatitis A on admission (A), 2 weeks after admission (B), and
controls
p value
Characteristics Healthy controls A B Control vs. A Control vs. B A vs. B
Number of patients 62 62 62
Age, years 9.1 ± 4.3 9.6 ± 3.6 9.6 ± 3.6
Male/female ratio 30/32 30/32 30/32
WBC (count/mm3)a 7800 (4800–11,000) 5440 (2100–27,400) 7197 (3900–6200) 0.023 0.021 NS
Platelet counts (count × 103/mm3)a 336 (176–967) 278 (22–748) 298 (69–554) NS NS 0.042
MPV (fL) 8.28 ± 1.13 9.47 ± 1.62 8.84 ± 1.48 <0.0001 <0.0001 0.005
AST (IU/L)a 27(11–33) 927 (34–4145) 33 (16–519) <0.0001 0.004 <0.0001
ALT (IU/L)a 14 (6–36) 1250 (36–4113) 35 (6–1358) <0.0001 <0.0001 <0.0001
T. bil (IU/L)a – 1 (0.3–17.2)
D. bil(IU/L)a – 0.67 (0.1–7.7)
PTT – 29.1 (18.1–46.9)
PT – 13.7 (10.7–35.1)
Parametric values were expressed as means with standard deviation. Significance was determined by p < 0.05
AST aspartate transaminase, ALT alanine transaminase, PT prothrombin time, aPTT activated partial thromboplastin time, MPV mean platelet volume, WBC white
blood cell, T.bil total bilirubin, D.bil direct bilirubin, NS not significant
aIf not normally distributed, values were presented as median (minimum-maximum)
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cytokines and thrombopoietin may have contributed to
elevation of MPV in patients with hepatitis A. The de-
crease of MPV after 2 weeks in the recovery phase also
supports this speculation.
Limitations
Our study had some limitations, such as its retrospective
design and lack of data of the cytokine levels of the
study group. Additionally, this study consists children
with hepatitis A who were hospitalized; thus, further
studies are needed for outpatients and the adult age
group.
Conclusions
Our study demonstrated that MPV values are increased
in children hospitalized with hepatitis A. However, pro-
spective studies with larger number of patients are
needed to assess the mechanism of increased MPV
values in hepatitis A.
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